Danish DES registry
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Cordis' Cypher sirolimus-eluting coronary stent has a lower nine-month target lesion revascularization rate than Boston Scientific's paclitaxel-eluting Taxus stent in the 4,432-patient Western Denmark Heart Registry, according to data published June 1 in Heart. In small vessels (less than 2.8 mm in diameter) the revascularization rates were 2.9% and 4.8% for Cypher and Taxus, respectively, a 40% difference in relative risk. In larger vessels, patients treated with Cypher had a 2.4% TLR rate versus 3% for Taxus, a statistically insignificant difference...